The feasibility of implementing recovery, psychosocial and pharmacological interventions for psychosis: comparison study by van der Krieke, Lian et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s13012-015-0262-9
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
van der Krieke, L., Bird, V., Leamy, M., Bacon, F., Dunn, R., Pesola, F., ... Slade, M. (2015). The feasibility of
implementing recovery, psychosocial and pharmacological interventions for psychosis: comparison study.
Implementation Science, 10(73). DOI: 10.1186/s13012-015-0262-9
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
RESEARCH Open Access
The feasibility of implementing recovery,
psychosocial and pharmacological interventions
for psychosis: comparison study
Lian van der Krieke1,2*, Victoria Bird2, Mary Leamy2, Faye Bacon2, Rebecca Dunn2, Francesca Pesola2,
Monika Janosik2, Clair Le Boutillier2, Julie Williams2 and Mike Slade2
Abstract
Background: Clinical guidelines for the treatment of people experiencing psychosis have existed for over a decade,
but implementation of recommended interventions is limited. Identifying influences on implementation may help
to reduce this translational gap. The Structured Assessment of Feasibility (SAFE) measure is a standardised
assessment of implementation blocks and enablers. The aim of this study was to characterise and compare the
implementation blocks and enablers for recommended psychosis interventions.
Methods: SAFE was used to evaluate and compare three groups of interventions recommended in the 2014 NICE
psychosis guideline: pharmacological (43 trials testing 5 interventions), psychosocial (65 trials testing 5 interventions),
and recovery (19 trials testing 5 interventions). The 127 trial reports rated with SAFE were supplemented by published
intervention manuals, research protocols, trial registrations and design papers. Differences in the number of blocks and
enablers across the three interventions were tested statistically, and feasibility profiles were generated.
Results: There was no difference between psychosocial and recovery interventions in the number of blocks or
enablers to implementation. Pharmacological interventions (a) had fewer blocks than both psychosocial interventions
(χ2(3) = 133.77, p < 0.001) and recovery interventions (χ2(3) = 104.67, p < 0.001) and (b) did not differ in number of
enablers from recovery interventions (χ2(3) = 0.74, p = 0.863) but had fewer enablers than psychosocial interventions
(χ2(3) = 28.92, p < 0.001). Potential adverse events associated with the intervention tend to be a block for pharmacological
interventions, whereas complexity of the intervention was the most consistent block for recovery and psychosocial
interventions.
Conclusions: Feasibility profiles show that pharmacological interventions are relatively easy to implement but can
sometimes involve risks. Psychosocial and recovery interventions are relatively complex but tend to be more flexible and
more often manualised. SAFE ratings can contribute to tackling the current implementation challenges in mental health
services, by providing a reporting guideline structure for researchers to maximise the potential for implementation and by
informing prioritisation decisions by clinical guideline developers and service managers.
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Background
Clinical guidelines for the treatment of people experien-
cing psychosis in the UK were published by the National
Institute for Health and Care Excellence (NICE) in 2014
[1], updating earlier guidelines published in 2002 and
2009. The guidelines cover a range of evidence-based
pharmacological and psychosocial interventions. How-
ever, the implementation of these interventions, particu-
larly the psychosocial interventions, is limited [2–4]. A
2007 report of the Healthcare Commission and the
Commission for Social Care Inspection stated that only
53 % of schizophrenia patients living in Britain received
NICE-recommended family intervention, and only 46 %
had access to NICE-recommended cognitive behavioural
therapy [5]. A more recent survey study among 187
schizophrenia patients in North-West England showed
that only 7 % of patients were offered and 5 % received
cognitive behavioural therapy. The percentages for fam-
ily intervention were again lower: 3 % of patients were
offered family intervention and only 1 % received it [6].
Guideline development and policy-making focus on
systematic reviews of efficacy and cost-effectiveness,
with the feasibility of an intervention somewhat ignored,
or considered following the recommendations [7]. This
relative disregard of the feasibility of the intervention
seems unhelpful, given the importance of feasibility in
implementation theory. The Consolidated Framework
For Implementation Research (CFIR), which provides a
comprehensive theoretical framework of key implementa-
tion constructs, comprises five major interacting domains
that influence implementation effectiveness [8]: outer
setting (the economic, political and social context within
which an organisation resides), inner setting (features of
structural, political and cultural contexts), characteristics
of individuals involved (who are affected by cultural,
organisational, professional and individual mindsets,
norms, interests and affiliations), the process of imple-
mentation (implementation may be actively promoted
with support from the inner or outer setting, there may be
sub-processes planned or unplanned, with a linear or non-
linear course, etc.) and intervention characteristics. An
intervention can be more or less feasible depending on,
for instance, the complexity of the intervention or its
adaptability to a particular setting. Since feasibility of the
intervention is identified as a domain that influence
implementation processes, it needs to be taken into
account when decisions are made about prioritisation or
recommendation of interventions. Therefore, the imple-
mentation feasibility of interventions is the focus of the
current study.
Our aim was to evaluate and compare the feasibility of
different interventions included within the NICE psych-
osis guidelines, using a standardised measure of feasibility
called Structured Assessment of Feasibility (SAFE; [7]).
We compared the feasibility of pharmacological, psycho-
social and recovery interventions.
Methods
Measures
The SAFE measure is a 16-item assessment of the feasi-
bility of an intervention for routine implementation [7].
In this measure, feasibility is defined as the cumulative
impact of different influences that affect the implemen-
tation of an intervention within a specific health care
practice. Each SAFE item was identified from implemen-
tation research, classified as either a block (eight items)
or an enabler (eight items) of implementation and rated
on a four-point scale (Yes, Partial, No, Unable to rate).
The eight-block items are:
 B1—Training: Does staff require specific training to
deliver the intervention?
 B2—Complexity: Is the intervention complex?
 B3—Time: Is the intervention time-consuming to
provide?
 B4—Support: Does the intervention include/require
ongoing support and supervision
 B5—Personnel: Does the intervention require
additional human resources?
 B6—Material: Does the intervention require
additional material resources?
 B7—Costs: Is the intervention costly?
 B8—Harms: Are there any known serious or adverse
events associated with the intervention?
The eight enabler items are:
 E1—Population: Is the intervention applicable to the
population of interest?
 E2—Manualisation: Is the intervention manualised?
 E3—Flexibility: Is the intervention flexible?
 E4—Effectiveness: Is the intervention likely to be
effective?
 E5—Saving: Is the intervention cost-saving?
 E6—Goals: Do the intended goals of the
intervention match the prioritised goals of the NHS?
 E7—Pilot: Can the intervention be piloted?
 E8—Reversibility: Is the intervention reversible?
SAFE has ‘excellent’ [9] inter-rater reliability (kappa =
0.84, 95 % CI 0.79–0.89) and test-retest reliability
(kappa = 0.89, 95 % CI 0.85–0.93) [7].
Procedure
We reviewed the 2014 NICE guidelines for psychosis and
schizophrenia in adults [1] to identify recommended inter-
ventions. Interventions were categorised into pharmaco-
logical, psychosocial and recovery interventions. This
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categorisation was guided by the aim of distinguishing
between (1) intervention type, namely medication versus
non-medication-based therapy, and (2) targeted outcomes,
namely clinical recovery (e.g. symptomatic relief, reduced
hospitalisation) versus personal recovery (i.e. being able to
live a meaningful and satisfying life beyond the illness
[10]). Pharmacological interventions were defined as
medication based and focused on clinical recovery out-
come, psychosocial interventions as non-medication based
and focused on clinical recovery outcomes and recovery
interventions as non-medication based and focused on
personal recovery outcomes.
Five interventions from each intervention category
which had the strongest recommendation in the NICE
guidelines, as reflected in the wording of the recommen-
dation (e.g. ‘offer’ , ‘should be offered’ or ‘consider offer-
ing’ versus ‘do not routinely offer’ or ‘do not offer’) were
selected for review. For each of these 15 interventions,
we searched all full reports of randomised controlled
trials (RCTs), published from 2000 onwards that are
referred to in the NICE guidelines. In the case of
multiple parallel or follow-up publications of the same
study, we selected the first publication. Trial reports
were supplemented by published intervention manuals,
research protocols, trial registrations and design papers
referred to in the trial reports. Trials were independently
rated using SAFE by two raters (RD and LvdK), who
double-rated 10 % of trials to check concordance.
Analysis
Chi-square tests were used to compare the overall pro-
portion of implementation blocks and enablers across
intervention categories. Although the SAFE manual
recommends to use individual item scores instead of
summary scores to account for unequal weight of items,
in this first analysis, we did use the total number of
blocks and enablers in order to gain a global overview of
blocks and enablers across the rather broad intervention
categories. In the chi-square tests, interventions (pharma-
cological, psychosocial and recovery) were crossed with
rating categories (Yes, Partial, No, Unable to rate), for
both blocks and enablers. So, we compared the weighted
frequency of Yes (n = 10), Partial (n = 45), No (n = 281)
and Unable (n = 8) ratings for blocks on pharmacological
interventions to the weighted frequency of Yes (n = 77),
Partial (n = 110), No (n = 231) and Unable (n = 102)
ratings for blocks on psychosocial interventions versus
the weighted frequency of Yes (n = 38), Partial (n = 30),
No (n = 63) and Unable (n = 21) ratings for blocks on
recovery interventions. In addition, we compared the
weighted frequency of Yes (n = 210), Partial (n = 38),
No (n = 51) and Unable (n = 45) ratings for enablers on
pharmacological interventions to the weighted fre-
quency of Yes (n = 358), Partial (n = 69), No (n = 23)
and Unable (n = 70) ratings for enablers on psycho-
social interventions versus the weighted frequency of
Yes (n = 108), Partial (n = 17), No (n = 8) and Unable
(n = 19) ratings for enablers on recovery interventions.
Post hoc tests were used to examine the proportion
of blocks and enablers in pairs: pharmacological inter-
ventions versus psychosocial interventions, psycho-
social interventions versus recovery interventions and
recovery interventions versus pharmacological interven-
tions. For the post hoc tests, a Bonferroni-corrected
significance level of 0.01 was taken.
Fisher’s exact tests were used to make pairwise compari-
sons of blocks and enablers on item level (i.e. separate
analyses for B1 to B8 and E1 to E8). In the latter compari-
sons, the four response categories (Yes, Partial, No,
Unable to rate) were restricted to the two categories Yes
versus ‘non-Yes’ because of small cell counts. So, we
crossed ‘Yes’ versus ‘non-Yes’ with intervention category
(pharmacological, psychosocial, recovery), for each block
and each enabler separately. For the pairwise comparisons,
the significance level was corrected to p < 0.002. As a
measure of effect size, we calculated Mantel-Haenszel
odds ratios, which provide a pooled odds ratio across
strata [11].
Graphic profiles of implementation blocks and
enablers were created to visualise the proportion of
reported blocks and enablers for each SAFE item per
intervention category. All four response categories are
presented (Yes, Partly, No, Unable to rate). The graphic
profiles were modified from the Cochrane ‘risk of bias’
graph recommended for use in systematic reviews,
which shows the proportion of low, high and unclear
risk of bias in the design of a study [12].
Results
The 15 included interventions and 127 related RCTs are
shown in Table 1.
Concordance on SAFE rating was kappa = 0.89 (95 %
CI 0.83–0.94), which can be considered ‘excellent’ [9].
Visual profiles of proportion of implementation blocks
and enablers for each intervention category are shown in
Fig. 1. These profiles show that psychosocial interven-
tions and recovery interventions have a relatively broad
range of blocks and enablers that partly overlap, whereas
pharmacological interventions have a less varied profile.
There was a significant difference in total number of
blocks (χ2(6) = 161.05, p < 0.000) and enablers (χ2(6) =
33.02, p < 0.000) between the pharmacological, psycho-
social and recovery intervention categories. Post hoc tests
showed no difference between psychosocial interventions
and recovery interventions for blocks (χ2(3) = 9.65, p =
0.02) or enablers (χ2(3) = 0.74, p = 0.863). Pharmacological
interventions had fewer blocks than both psychosocial
interventions (χ2(3) = 133.77, p < 0.001) and recovery
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interventions (χ(3)2 = 104.67, p < 0.001). Pharmacological
interventions did not differ in number of enablers from re-
covery interventions (χ2 = 0.74, p = 0.863) but had fewer
enablers than psychosocial interventions (χ2(3) = 28.92,
p < 0.001).
Differences between specific blocks and enablers
across intervention categories are shown in Table 2,
showing for example that pharmacological interventions
had fewer blocks relating to complexity than psycho-
social interventions.
Discussion
This study investigated the implementation feasibility of
pharmacological, psychosocial and recovery interven-
tions recommended in the NICE guidelines for adults
experiencing psychosis. Psychosocial and recovery inter-
ventions have the same number of blocks and enablers,
and they differ in their profile from pharmacological
interventions. Both psychosocial interventions and re-
covery interventions can be complex and consist of
multiple interacting components. In addition, recovery
interventions can require additional staff to be provided.
However, recovery and psychosocial interventions have
the advantage that they are often manualised and that
they can be easily tailored to a specific situation or con-
text. Pharmacological interventions have fewer blocks,
but visual profiles show that they tend to have a higher
risk for adverse events.
Strengths and limitations
This is the first study to assess the implementation feasi-
bility of interventions recommended in the NICE guide-
lines for people with psychosis, thus offering an approach
which can inform both guideline development processes
and routine implementation of interventions. We identify
five limitations. First, not all recently published studies
were included. The evidence for psychosocial and recovery
interventions was updated up to the publication date of
the NICE guidelines, which was February 2014. This is
one reason for the small number of RCT reports of recov-
ery interventions reviewed. Moreover, in contrast to the
psychosocial and recovery interventions, the evidence on
pharmacological interventions was not updated in the
2014 NICE guidelines. Therefore, for this intervention
category, we only included publications up to 2009, which
Table 1 Included interventions for psychosis (n = 15)
Recovery interventions RCTs Psychosocial interventions RCTs Pharmacological interventions RCTs
Illness Management and Recovery (IMR) 4 Cognitive behavioural therapy (CBT) 25 Acute treatment—oral antipsychotics
not otherwise specified
24
Wellness Recovery Action Planning
(WRAP)
1 Family intervention (FI) 20 Relapse prevention—oral antipsychotics
not otherwise specified
8
Individual Placement and Support (IPS) 12 Behavioural lifestyle intervention
(combined physical activity and
healthy eating)
15 Relapse prevention—depot medication 2
Recovery Workbook 1 Arts therapy 4 Treatment resistance—clozapine 2
Building Recovery of Individual
Dreams and Goals through Education
and Support (BRIDGES)
1 Psychoanalytic/psychodynamic therapy 1 Smoking cessation—bupropion or
varenicline
7
Total RCTs: 19 65 43
Fig. 1 Feasibility profiles showing pooled blocks and enablers for three categories of intervention
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might have introduced a bias to our sample of pharmaco-
logical papers.
Second, our analysis of implementation feasibility of
interventions was based on published documents, so
SAFE ratings may be influenced by reporting quality
rather than the actual intervention. We addressed this
issue by accessing published manuals, design papers,
research protocols and trial registrations alongside trial
Table 2 Pairwise comparisons of blocks and enablers between intervention categories
Item Pharmacological versus psychosocial Psychosocial versus recovery Pharmacological versus recovery
χ2(df), p, </>, odds ratio χ2(df), p, </>, odds ratio χ2(df), p, </>, odds ratio
B1—Training 4.825(1) 2.501(1) 11.259(1)
0.047 0.180 0.002
B2—Complexity 17.413(1) 0.673(1) 19.763(1)
<0.001 0.435 <0.001
< - <
24.585 - 37.800
B3—Time - 0.002(1) -
N/Aa 1.000 N/Aa
B4—Support - 1.198(1) -
N/Aa 0.313 N/Aa
B5—Personnel 4.825(1) 11.244(1) 22.850(1)
0.047 0.002 <0.001
- - <
- - 46.667
B6—Material - 0.303(1) -
N/Aa 1.000 N/Aa
- 0.546 -
B7—Costs - 2.768(1) -
N/Aa 0.126 N/Aa
B8—Harms N/Aa N/Aa N/Aa
E1- Population 0.443(1) 0.001(1) 0.224(1)
0.737 1.000 0.638
E2- Manualisation 25.546(1) 0.001(1) 19.763(1)
<0.001 1.000 <0.001
< - <
38.294 - 37.800
E3- Flexibility 19.320(1) 0.299(1) 14.600(1)
<0.001 0.788 <0.001
< - <
7.000 - 9.479
E4- Effectiveness 2.389(1) 2.299(1) 0.147(1)
0.149 0.176 1.000
E5—Saving - 3.449(1) -
N/Aa 0.127 N/Aa
E6—Goals N/Aa N/Aa N/Aa
E7—Pilot - 3.771(1) -
N/Aa 0.114 N/Aa
E8—Reversibility N/Aa N/Aa N/Aa
aAnalyses could not be run because at least one of the frequencies was zero
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reports. However, in some cases, these additional docu-
ments did not provide all information needed. For
instance, information about costs and cost savings was
often limited. In combination with the relatively high
threshold used in SAFE ratings for an intervention to be
identified as costly, this may partly explain why no
differences in cost and cost savings were found between
intervention categories. Some specific items, such as
costs, may therefore benefit from more detailed analysis
to inform recommendations. Related to this limitation,
reports of RCTs describe what happened in the context
of a trial, when implementation might be more standar-
dised and less flexible than in routine clinical practice. For
example, in most reviewed pharmacological trials, medica-
tion was prescribed either in a fixed dosage (i.e. the same
for each service user) or in a combination of partly fixed
and partly variable dosage (e.g. a fixed dosage for the first
few weeks, and a variable dosage in later stages of the
trial), whereas changes to dosage outside of a trial context
may be more variable. Our study might therefore have
underestimated the actual flexibility of interventions.
However, our approach to using RCTs is consistent with
the methodology used to develop guidelines, in that the
efficacy estimates come from controlled conditions, which
may differ from the efficacy within routine implementation.
A third limitation concerns rating the extent to which
interventions were manualised. The difference in man-
ualisation between psychosocial and recovery interven-
tions versus pharmacological interventions may be
explained by the fact that in almost all pharmacological
interventions, the only structured part was the specified
medication dosages. Although dosage may be a crucial
component in the delivery of a pharmacological interven-
tion, NICE guidelines emphasise that pharmacotherapy is
a trajectory including discussion of risks and benefits and
careful recording and monitoring of response and side
effects. If this trajectory was not structured or specified in
most trial reports, we considered the pharmacological
intervention not to be manualised. The implication of our
approach may be an underestimation of manualisation in
pharmacological interventions.
The fourth limitation is that we could not perform
quantitative analyses for all comparisons of blocks and
enablers because of empty cells (i.e. zero counts for
blocks and enablers) for some items. In these cases, we
had to rely on the visual profiles shown in Fig. 1. A final
limitation is that we rated only the 15 interventions
listed in the NICE guidelines with the strongest evidence
so did not provide a comprehensive overview of all
interventions.
Implications
This study offers an approach which may contribute to
tackling the current implementation challenges in
psychiatry by addressing one of the major implementa-
tion domains identified in implementation theory,
namely feasibility of the intervention [8]. Assessment of
intervention feasibility can inform the development
process of clinical guidelines. Current guidelines are
primarily based on evidence reviews with a focus on effi-
cacy and cost-effectiveness [13]. We propose that guide-
line development would benefit from more weight being
put on the feasibility of interventions. Incorporating
SAFE ratings into the evidence appraisal would provide
a metric for guideline developers to take into account
those aspects that might hamper or facilitate successful
implementation. For instance, if an intervention A has
higher efficacy than intervention B but also has a higher
risk for doing harm, then this may be a reason to give
higher recommendation to intervention B. In addition, if
an intervention is cost-effective but has also found to be
highly complex in terms of implementation feasibility,
this should be balanced in the recommendations.
Balanced recommendations can be made which differen-
tiate between settings in which implementation is more
or less feasible.
SAFE items were sometimes scored as ‘unable to rate’
because trial reports and manuals did not provide
complete information. Information was particularly lack-
ing regarding potential blocks in staff training, time
spent on the delivery of the intervention, ongoing super-
vision and cost-saving potential of the intervention.
Future studies might benefit from using SAFE reporting
guidelines, which parallel the SAFE assessment items
[7], in a way that the PRISMA [14] and CONSORT [15]
statements guide the reporting of systematic reviews and
RCTs. These reporting guidelines may help researchers
to put more emphasis on feasibility issues, both in the
initial design and the final reporting of trials.
Finally, feasibility profiles have relevance for service
development as they can support service managers in
identifying the important and evidence-based feasibility
issues that are likely to arise during translation of evi-
dence into practice. SAFE ratings can provide a pre-
implementation assessment; an important step in the
implementation process of evidence-based interventions
into everyday clinical practice [16–18]. For instance,
looking at the feasibility profiles of recovery interven-
tions in Fig. 1, service managers can conclude that, for
the included interventions, (1) they can be sure that
recovery interventions are applicable to service users
with psychosis, that the goals of the intervention match
the prioritised goals of the NHS, that there is evidence
of effectiveness (these items all have long blue bars indi-
cating that they are rated as enablers), (2) they do not
have to worry about negative consequences when the in-
terventions would be stopped (low risk of irreversibility),
(3) the implementation of these interventions can benefit
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from the fact that recovery interventions are often man-
ualised and can be tailored to context and situation, but
that (4) they should take into account that additional
staff is needed to provide the interventions and that the
interventions often consist of multiple interacting com-
ponents, which might mean that they have to appoint a
skilled person to supervise implementation processes.
Assessment of potential blocks and enablers, such as
staff time to tailor interventions or to manage the inter-
action between components of a complex intervention,
or the availability of manuals, allows for the creation of
an implementation plan in which priorities are set and
problems can be anticipated. This enables service man-
agers to allocate resources efficiently and to speed the
uptake of interventions by clinical staff.
Conclusion
SAFE ratings have the potential to be used during the
clinical guideline development process to make feasibil-
ity assessment a routine component of evidence-based
appraisal. The study highlighted how more attention
should focus on detailing the complexity and potential
harms of an intervention when reporting the results of a
study. Service managers can use SAFE profiles to inform
decisions about resource allocation so that more patients
have access to recommended treatment.
Abbreviations
NICE: National Institute for Health and Care Excellence; SAFE: Structured
Assessment of Feasibility; RCT: randomised controlled trial.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
VB and MS designed the study, with the help of LvdK. LvdK drafted the
manuscript. LvdK and RD performed the SAFE ratings. All authors
participated in the interpretation of the results, critically reviewed, and
approved the final manuscript.
Received: 17 November 2014 Accepted: 15 May 2015
References
1. National Institute for Health and Care Excellence. Psychosis and
Schizophrenia in adults. The NICE guideline on treatment and management.
CG178. London: National Institute for Health and Care Excellence; 2014.
2. Sederer LI. Science to practice: making what we know what we actually do.
Schizophr Bull. 2009;35(4):714–8.
3. Barbui C, Girlanda F, Ay E, Cipriani A, Becker T, Koesters M. Implementation
of treatment guidelines for specialist mental health care. Cochrane
Database Syst Rev. 2014;1:CD009780.
4. Michie S, Pilling S, Garety P, Whitty P, Eccles MP, Johnston M, et al.
Difficulties implementing a mental health guideline: an exploratory
investigation using psychological theory. Implement Sci. 2007;2:8.
5. Healthcare Commission and the Commission for Social Care Inspection.
No voice, no choice: a joint review of adult community mental health
services in England. London: HMSO; 2009.
6. Haddock G, Eisner E, Boone C, Davies G, Coogan C, Barrowclough C. An
investigation of the implementation of NICE-recommended CBT interventions
for people with schizophrenia. J Ment Health. 2014;23(4):162–5.
7. Bird VJ, Le Boutillier C, Leamy M, Williams J, Bradstreet S, Slade M. Evaluating
the feasibility of complex interventions in mental health services:
standardised measure and reporting guidelines. Br J Psychiatry.
2014;204:316–21.
8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC.
Fostering implementation of health services research findings into practice:
a consolidated framework for advancing implementation science.
Implement Sci. 2009;4:50-5908-4-50.
9. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics. 1977;33(1):159–74.
10. Slade M. Personal recovery and mental illness. A guide for mental health
professionals. firstth ed. New York: Cambridge University Press; 2009.
11. Mannocci A. The Mantel-Haenszel procedure. 50 years of the statistical
method for confounders control. Ital J. Public Health. 2009;6(4):338–40.
12. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. 2011.
13. Berry K, Haddock G. The implementation of the NICE guidelines for
schizophrenia: barriers to the implementation of psychological interventions
and recommendations for the future. Psychol Psychother. 2008;81(Pt 4):419–36.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. J Clin Epidemiol. 2009;62(10):1006–12.
15. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010
statement: updated guidelines for reporting parallel group randomised
trials. PLoS Med. 2010;7(3):e1000251.
16. Stetler CB, Legro MW, Wallace CM, Bowman C, Guihan M, Hagedorn H, et al.
The role of formative evaluation in implementation research and the QUERI
experience. J Gen Intern Med. 2006;21 Suppl 2:S1–8.
17. Mendel P, Meredith LS, Schoenbaum M, Sherbourne CD, Wells KB.
Interventions in organizational and community context: a framework for
building evidence on dissemination and implementation in health services
research. Adm Policy Ment Health. 2008;35(1–2):21–37.
18. Kilbourne AM, Neumann MS, Pincus HA, Bauer MS, Stall R. Implementing
evidence-based interventions in health care: application of the replicating
effective programs framework. Implement Sci. 2007;2:42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Krieke et al. Implementation Science  (2015) 10:73 Page 7 of 7
